Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6738-6744

  Lev Ari, Shahar ^a,b   Strier, Ludmila ^b   Kazanov, Diana ^b   Madar Shapiro, Liora ^b   Dvory Sobol, Hadas ^a,b   Pinchuk, Ilya ^b   Marian, Brigitte ^c   Lichtenberg, Dov ^b   Arber, Nadir ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2; ROFECOXIB;

ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL STRAIN; CELL STRAIN CACO 2; CELL STRAIN HT29; CELL STRAIN SW 480; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; ONCOGENE K RAS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; CACO-2 CELLS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HT29 CELLS; HUMANS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TIME FACTORS;

EID: 25144513892     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0171     Document Type: Article

References (40)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. (2003). Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
3. Arber N, Du Bois RN. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep 1999;1:441-8.
4. Solomon SD, McMurray JJ, Pfeffer MA, et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
5. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-51.
6. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000 Apr;275:11397-403.
7. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai SJ. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor γ in rheumatoid synovial cells. J Pharmacol Exp Ther 2002;302:18-25.
8. Kazanov D, Dvory-Sobol H, Pick M, et al. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res 2004;10:267-71.
9. Rao CV, Kawamori T, Hamid R, Reddy BS. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999;20:641-4.
10. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98.
11. Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999;59:597-601.
12. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004;101:2351-62.
13. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001;172:111-8.
14. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995;270:24995-5000.
15. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 2000;4:1-6.
16. Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 1999;5:1884-91.
17. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999;20:445-51.
18. Hood WF, Gierse JK, Isakson PC, et al. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol 2003;63:870-7.
19. Arber N, Man EK, Sgambato A, et al. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes. Gastroenterology 1997;113:1892-900.
20. Arber N, Doki Y, Han EK, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997;57:1569-74.
21. Pinchuk I, Lichtenberg D. Continuous monitoring of intermediates and final products of oxidation of low density lipoprotein by means of UV-spectroscopy. Free Radic Res 1996;24:351-60.
22. Schnitzer E, Pinchuk I, Bor I, Fainaru I, Lichtenberg D. The effect of albumin on copper-induced LDL oxidation. Biochim Biophys Acta 1997;1344:300-11.
23. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002;62:1567-72.
24. Smith ML, Hawcroft G, Hull MA. The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000;36:664-74.
25. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
26. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
27. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999;117:838-47.
28. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H. Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 1999;59:44-7.
29. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
30. Agarwal BB, Swaroop P, Protiva P, Raj SV, Shirin H, Holt PR. Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 2003;8:649-54.
31. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
32. Chaudhary LR, Hruska KA. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 2003;89:1-5.
33. Kulp SK, Yang YT, Hung CC, et al. phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51
34. Shishodia S, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-κB by suppressing activation of IκBα kinase in human nonsmall cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 2004;64:5004-12.
35. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003;24:1269-79.
36. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Non-steroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58.
37. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin down-regulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20:7597-609.
38. Rao CV, Kawamori T, Hamid R, Reddy BS. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999;20:641-4.
39. Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 2003;9:3503-13.
40. Fujisawa S, Atsumi T, Ishihara M, Kadoma Y. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Res 2004;24:563-9.